Evolus Inc. Common Stock (EOLS)

FairStock Score: 31/100 — RISKY

Key Financials

Concerns

• Altman Z-Score of -2.5 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Evolus Inc. Common Stock is a micro-cap healthcare company valued at $342 million. The business generates $302 million in annual revenue with a 0.0% net margin. From a quality standpoint, Evolus shows solid Piotroski F-Score of 6/9 and distressed Altman Z-Score of -2.5 warrants caution. On valuation, the stock is 3.1% FCF yield. Growth dynamics show revenue growing at 14.4% and profit growth of 101.9%. Our composite FairStock Score of 31/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer